Found 656 hits of Enzyme Inhibition Constant Data Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kJ/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208929
(US9266878, 155a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(33-26-21(25(30)31-16-32-26)14-13-18-7-5-8-19(15-37)34-18)27-35-23-12-6-11-22(29)24(23)28(38)36(27)20-9-3-2-4-10-20/h2-12,16-17,37H,15H2,1H3,(H3,30,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | >1 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208871
(US9266878, 97a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1 |r| Show InChI InChI=1S/C26H18ClFN8O/c1-15(34-24-20(23(29)32-14-33-24)7-6-18-13-30-9-10-31-18)25-35-22-8-5-17(28)12-21(22)26(37)36(25)19-4-2-3-16(27)11-19/h2-5,8-15H,1H3,(H3,29,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208873
(US9266878, 99a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C27H18F3N7O/c1-15(35-25-20(24(31)33-14-34-25)11-10-18-9-8-17(29)13-32-18)26-36-22-7-3-6-21(30)23(22)27(38)37(26)19-5-2-4-16(28)12-19/h2-9,12-15H,1H3,(H3,31,33,34,35)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208881
(US9266878, 107a)Show SMILES CC[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H19F3N8O/c1-2-21(36-25-19(24(31)34-14-35-25)7-6-17-13-32-8-9-33-17)26-37-22-5-3-4-20(30)23(22)27(39)38(26)18-11-15(28)10-16(29)12-18/h3-5,8-14,21H,2H2,1H3,(H3,31,34,35,36)/t21-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208885
(US9266878, 111a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C28H20F2N6O/c1-17(34-26-21(25(31)32-16-33-26)14-13-18-7-3-2-4-8-18)27-35-23-12-6-11-22(30)24(23)28(37)36(27)20-10-5-9-19(29)15-20/h2-12,15-17H,1H3,(H3,31,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208892
(US9266878, 118a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18ClN9O/c1-15(33-23-18(22(27)31-14-32-23)8-7-16-12-29-10-11-30-16)24-34-20-6-2-5-19(26)21(20)25(36)35(24)17-4-3-9-28-13-17/h2-6,9-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208906
(US9266878, 132a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-22-9-5-8-21(29)23(22)27(40)39(26)19-6-3-2-4-7-19)37-25-20(24(33)35-15-36-25)13-12-18-11-10-17(14-34-18)28(30,31)32/h2-11,14-16H,1H3,(H3,33,35,36,37)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208909
(US9266878, 135a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(N)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(27-36-22-9-5-8-21(29)23(22)28(39)37(27)19-6-3-2-4-7-19)35-26-20(24(30)33-15-34-26)13-12-18-11-10-17(14-32-18)25(31)38/h2-11,14-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208926
(US9266878, 152a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccc1C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O2/c1-17(28-36-24-12-6-11-22(30)25(24)29(39)37(28)19-8-4-3-5-9-19)35-27-21(26(31)33-16-34-27)13-14-23-20(18(2)38)10-7-15-32-23/h3-12,15-17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208928
(US9266878, 154a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(CO)ccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-21(25(30)32-16-33-26)11-10-19-14-18(15-37)12-13-31-19)27-35-23-9-5-8-22(29)24(23)28(38)36(27)20-6-3-2-4-7-20/h2-9,12-14,16-17,37H,15H2,1H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208934
(US9266878, 160a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(O)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClN7O3/c1-16(26-35-22-9-5-8-21(29)23(22)27(37)36(26)19-6-3-2-4-7-19)34-25-20(24(30)32-15-33-25)11-10-18-14-17(28(38)39)12-13-31-18/h2-9,12-16H,1H3,(H,38,39)(H3,30,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208935
(US9266878, 161a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(c1)C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C30H23ClN6O2/c1-18(29-36-25-13-7-12-24(31)26(25)30(39)37(29)22-10-4-3-5-11-22)35-28-23(27(32)33-17-34-28)15-14-20-8-6-9-21(16-20)19(2)38/h3-13,16-18H,1-2H3,(H3,32,33,34,35)/t18-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208808
(US9266878, 33a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)nc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H20ClN9O/c1-15(34-23-18(22(28)32-14-33-23)11-10-16-12-30-26(29)31-13-16)24-35-20-9-5-8-19(27)21(20)25(37)36(24)17-6-3-2-4-7-17/h2-9,12-15H,1H3,(H2,29,30,31)(H3,28,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208821
(US9266878, 46a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21ClN8OS/c1-16(27-36-22-9-5-8-20(30)24(22)28(39)38(27)18-6-3-2-4-7-18)35-26-19(25(31)33-15-34-26)12-10-17-11-13-21-23(14-17)40-29(32)37-21/h2-9,11,13-16H,1H3,(H2,32,37)(H3,31,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208824
(US9266878, 49a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cn[nH]c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
PDB
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208855
(US9266878, 80a)Show SMILES COc1cccnc1C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(34-26-19(25(30)32-16-33-26)13-14-21-23(38-2)12-7-15-31-21)27-35-22-11-6-10-20(29)24(22)28(37)36(27)18-8-4-3-5-9-18/h3-12,15-17H,1-2H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208906
(US9266878, 132a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(cn1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-22-9-5-8-21(29)23(22)27(40)39(26)19-6-3-2-4-7-19)37-25-20(24(33)35-15-36-25)13-12-18-11-10-17(14-34-18)28(30,31)32/h2-11,14-16H,1H3,(H3,33,35,36,37)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208870
(US9266878, 96a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2ccc(F)cc2c(=O)n1-c1cccc(Cl)c1 |r| Show InChI InChI=1S/C27H18ClF2N7O/c1-15(35-25-21(24(31)33-14-34-25)9-8-19-7-5-18(30)13-32-19)26-36-23-10-6-17(29)12-22(23)27(38)37(26)20-4-2-3-16(28)11-20/h2-7,10-15H,1H3,(H3,31,33,34,35)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208904
(US9266878, 130a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(CNS(C)(=O)=O)c1 |r| Show InChI InChI=1S/C29H24ClFN8O3S/c1-17(37-27-22(26(32)34-16-35-27)12-11-20-10-9-19(31)15-33-20)28-38-24-8-4-7-23(30)25(24)29(40)39(28)21-6-3-5-18(13-21)14-36-43(2,41)42/h3-10,13,15-17,36H,14H2,1-2H3,(H3,32,34,35,37)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208914
(US9266878, 140a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)c(C)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClFN7O/c1-16-22(30)14-12-18(34-16)11-13-20-25(31)32-15-33-26(20)35-17(2)27-36-23-10-6-9-21(29)24(23)28(38)37(27)19-7-4-3-5-8-19/h3-10,12,14-15,17H,1-2H3,(H3,31,32,33,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208923
(US9266878, 149a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClF2N7O/c1-16(27-37-22-9-5-8-21(29)23(22)28(39)38(27)19-6-3-2-4-7-19)36-26-20(25(32)34-15-35-26)11-10-18-14-17(24(30)31)12-13-33-18/h2-9,12-16,24H,1H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208927
(US9266878, 153a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(n1)C(C)=O)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O2/c1-17(28-36-24-13-7-11-22(30)25(24)29(39)37(28)20-9-4-3-5-10-20)34-27-21(26(31)32-16-33-27)15-14-19-8-6-12-23(35-19)18(2)38/h3-13,16-17H,1-2H3,(H3,31,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208929
(US9266878, 155a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CO)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22ClN7O2/c1-17(33-26-21(25(30)31-16-32-26)14-13-18-7-5-8-19(15-37)34-18)27-35-23-12-6-11-22(29)24(23)28(38)36(27)20-9-3-2-4-10-20/h2-12,16-17,37H,15H2,1H3,(H3,30,31,32,33)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208933
(US9266878, 159a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(CN)n1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H23ClN8O/c1-17(34-26-21(25(31)32-16-33-26)14-13-18-7-5-8-19(15-30)35-18)27-36-23-12-6-11-22(29)24(23)28(38)37(27)20-9-3-2-4-10-20/h2-12,16-17H,15,30H2,1H3,(H3,31,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208938
(US9266878, 164a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(C)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H20ClF2N7O/c1-15-6-7-19(33-13-15)8-9-21-25(32)34-14-35-26(21)36-16(2)27-37-23-5-3-4-22(29)24(23)28(39)38(27)20-11-17(30)10-18(31)12-20/h3-7,10-14,16H,1-2H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208810
(US9266878, 35a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(N)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H21ClN8O/c1-16(34-25-20(24(30)32-15-33-25)13-12-18-11-10-17(29)14-31-18)26-35-22-9-5-8-21(28)23(22)27(37)36(26)19-6-3-2-4-7-19/h2-11,14-16H,29H2,1H3,(H3,30,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208795
(US9266878, 18a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClF3N8O/c1-15(26-39-21-9-5-8-20(29)23(21)27(41)40(26)17-6-3-2-4-7-17)38-25-18(24(34)36-14-37-25)11-10-16-13-35-22(33)12-19(16)28(30,31)32/h2-9,12-15H,1H3,(H2,33,35)(H3,34,36,37,38)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208923
(US9266878, 149a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cc(ccn1)C(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClF2N7O/c1-16(27-37-22-9-5-8-21(29)23(22)28(39)38(27)19-6-3-2-4-7-19)36-26-20(25(32)34-15-35-26)11-10-18-14-17(24(30)31)12-13-33-18/h2-9,12-16,24H,1H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208783
(US9266878, 6a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(F)ccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H18ClF2N7O/c1-15(35-25-19(24(31)33-14-34-25)10-9-17-8-7-16(29)13-32-17)26-36-23-21(30)12-11-20(28)22(23)27(38)37(26)18-5-3-2-4-6-18/h2-8,11-15H,1H3,(H3,31,33,34,35)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208789
(US9266878, 12a)Show SMILES COc1ccc(nc1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2c(F)cccc2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H22FN7O2/c1-17(34-26-22(25(30)32-16-33-26)14-12-18-11-13-20(38-2)15-31-18)27-35-24-21(9-6-10-23(24)29)28(37)36(27)19-7-4-3-5-8-19/h3-11,13,15-17H,1-2H3,(H3,30,32,33,34)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208813
(US10221197, Compound 37 | US9266878, 38a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)C(N)=O |r| Show InChI InChI=1S/C28H21ClN8O2/c1-16(35-26-20(24(30)33-15-34-26)12-11-18-7-2-3-13-32-18)27-36-22-10-5-9-21(29)23(22)28(39)37(27)19-8-4-6-17(14-19)25(31)38/h2-10,13-16H,1H3,(H2,31,38)(H3,30,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208815
(US9266878, 40a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)S(N)(=O)=O |r| Show InChI InChI=1S/C27H21ClN8O3S/c1-16(34-25-20(24(29)32-15-33-25)12-11-17-6-2-3-13-31-17)26-35-22-10-5-9-21(28)23(22)27(37)36(26)18-7-4-8-19(14-18)40(30,38)39/h2-10,13-16H,1H3,(H2,30,38,39)(H3,29,32,33,34)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208818
(US9266878, 43a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccnc1)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C27H18ClF2N7O/c1-15(35-25-20(24(31)33-14-34-25)8-7-16-4-3-9-32-13-16)26-36-22-6-2-5-21(28)23(22)27(38)37(26)19-11-17(29)10-18(30)12-19/h2-6,9-15H,1H3,(H3,31,33,34,35)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208822
(US9266878, 47a)Show SMILES COc1cc(F)cc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClFN6O2/c1-17(28-36-24-10-6-9-23(30)25(24)29(38)37(28)20-7-4-3-5-8-20)35-27-22(26(32)33-16-34-27)12-11-18-13-19(31)15-21(14-18)39-2/h3-10,13-17H,1-2H3,(H3,32,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208827
(US9266878, 52a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(O)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C27H20FN7O2/c1-16(33-25-20(24(29)31-15-32-25)13-12-18-11-10-17(28)14-30-18)26-34-21-8-5-9-22(36)23(21)27(37)35(26)19-6-3-2-4-7-19/h2-11,14-16,36H,1H3,(H3,29,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208828
(US9266878, 53a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2c(C)ccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H21ClFN7O/c1-16-8-13-22(29)23-24(16)36-27(37(28(23)38)20-6-4-3-5-7-20)17(2)35-26-21(25(31)33-15-34-26)12-11-19-10-9-18(30)14-32-19/h3-10,13-15,17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208863
(US9266878, 89a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(Cl)c1 |r| Show InChI InChI=1S/C26H18Cl2N8O/c1-15(34-24-19(23(29)32-14-33-24)9-8-17-13-30-10-11-31-17)25-35-21-7-3-6-20(28)22(21)26(37)36(25)18-5-2-4-16(27)12-18/h2-7,10-15H,1H3,(H3,29,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208866
(US9266878, 92a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)C#N |r| Show InChI InChI=1S/C28H18ClFN8O/c1-16(36-26-21(25(32)34-15-35-26)11-10-19-9-8-18(30)14-33-19)27-37-23-7-3-6-22(29)24(23)28(39)38(27)20-5-2-4-17(12-20)13-31/h2-9,12,14-16H,1H3,(H3,32,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208875
(US9266878, 101a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccc(F)c1 |r| Show InChI InChI=1S/C26H18F2N8O/c1-15(34-24-19(23(29)32-14-33-24)9-8-17-13-30-10-11-31-17)25-35-21-7-3-6-20(28)22(21)26(37)36(25)18-5-2-4-16(27)12-18/h2-7,10-15H,1H3,(H3,29,32,33,34)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208888
(US9266878, 114a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccccc1)c1nc2cccc(C#N)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21N7O/c1-19(34-27-23(26(31)32-18-33-27)16-15-20-9-4-2-5-10-20)28-35-24-14-8-11-21(17-30)25(24)29(37)36(28)22-12-6-3-7-13-22/h2-14,18-19H,1H3,(H3,31,32,33,34)/t19-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208889
(US9266878, 115a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnccn1)c1nc2cccc(F)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18FN9O/c1-15(33-23-18(22(27)31-14-32-23)8-7-16-12-29-10-11-30-16)24-34-20-6-2-5-19(26)21(20)25(36)35(24)17-4-3-9-28-13-17/h2-6,9-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208891
(US9266878, 117a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccnc1 |r| Show InChI InChI=1S/C25H18ClN9O/c1-15(33-23-17(22(27)31-14-32-23)8-9-20-29-11-4-12-30-20)24-34-19-7-2-6-18(26)21(19)25(36)35(24)16-5-3-10-28-13-16/h2-7,10-15H,1H3,(H3,27,31,32,33)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208925
(US9266878, 151a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cccc(n1)C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H19ClF3N7O/c1-16(26-38-21-11-6-10-20(29)23(21)27(40)39(26)18-8-3-2-4-9-18)36-25-19(24(33)34-15-35-25)14-13-17-7-5-12-22(37-17)28(30,31)32/h2-12,15-16H,1H3,(H3,33,34,35,36)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208932
(US9266878, 158a)Show SMILES COC(=O)c1ccnc(c1)C#Cc1c(N)ncnc1N[C@@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H22ClN7O3/c1-17(27-36-23-10-6-9-22(30)24(23)28(38)37(27)20-7-4-3-5-8-20)35-26-21(25(31)33-16-34-26)12-11-19-15-18(13-14-32-19)29(39)40-2/h3-10,13-17H,1-2H3,(H3,31,33,34,35)/t17-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208794
(US9266878, 17a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C28H18ClF5N8O/c1-13(26-41-21-4-2-3-20(29)23(21)27(43)42(26)17-8-15(30)7-16(31)9-17)40-25-18(24(36)38-12-39-25)6-5-14-11-37-22(35)10-19(14)28(32,33)34/h2-4,7-13H,1H3,(H2,35,37)(H3,36,38,39,40)/t13-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
(Homo sapiens (Human)) | BDBM208795
(US9266878, 18a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cnc(N)cc1C(F)(F)F)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C28H20ClF3N8O/c1-15(26-39-21-9-5-8-20(29)23(21)27(41)40(26)17-6-3-2-4-7-17)38-25-18(24(34)36-14-37-25)11-10-16-13-35-22(33)12-19(16)28(30,31)32/h2-9,12-15H,1H3,(H2,33,35)(H3,34,36,37,38)/t15-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
(Homo sapiens (Human)) | BDBM208821
(US9266878, 46a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc2nc(N)sc2c1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C29H21ClN8OS/c1-16(27-36-22-9-5-8-20(30)24(22)28(39)38(27)18-6-3-2-4-7-18)35-26-19(25(31)33-15-34-26)12-10-17-11-13-21-23(14-17)40-29(32)37-21/h2-9,11,13-16H,1H3,(H2,32,37)(H3,31,33,34,35)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208797
(US9266878, 20b)Show SMILES CC(O)C#Cc1c(N)ncnc1N[C@H](C)c1nc2cccc(Cl)c2c(=O)n1-c1cc(F)cc(F)c1 |r| Show InChI InChI=1S/C24H19ClF2N6O2/c1-12(34)6-7-17-21(28)29-11-30-22(17)31-13(2)23-32-19-5-3-4-18(25)20(19)24(35)33(23)16-9-14(26)8-15(27)10-16/h3-5,8-13,34H,1-2H3,(H3,28,29,30,31)/t12?,13-/m1/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208817
(US9266878, 42a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1cncnc1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1 |r| Show InChI InChI=1S/C26H19ClN8O/c1-16(33-24-19(23(28)31-15-32-24)11-10-17-12-29-14-30-13-17)25-34-21-9-5-8-20(27)22(21)26(36)35(25)18-6-3-2-4-7-18/h2-9,12-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
(Homo sapiens (Human)) | BDBM208835
(US9266878, 60a)Show SMILES C[C@H](Nc1ncnc(N)c1C#Cc1ccc(F)cn1)c1nc2cccc(Cl)c2c(=O)n1-c1cccc(c1)-c1ccccc1 |r| Show InChI InChI=1S/C33H23ClFN7O/c1-20(40-31-26(30(36)38-19-39-31)16-15-24-14-13-23(35)18-37-24)32-41-28-12-6-11-27(34)29(28)33(43)42(32)25-10-5-9-22(17-25)21-7-3-2-4-8-21/h2-14,17-20H,1H3,(H3,36,38,39,40)/t20-/m0/s1 | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| PC cid
PC sid
UniChem
| US Patent
| n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Gilead Calistoga LLC
US Patent
| Assay Description
PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2xKm ATP (100-300 uM), 10 uM PIP2, 5% glycerol,... |
US Patent US9266878 (2016)
BindingDB Entry DOI: 10.7270/Q28K77W5 |
More data for this
Ligand-Target Pair | |
Search and Browse
